Comaschi et al., 2006 (23) |
Pioglitazone + sulfonylurea |
|
6 months |
Significant and comparable improvementsin HbA1c at 12 months (p = 0.0001) |
Significant improvement across alllipid parameters |
|
Pioglitazone + metformin |
|
|
|
|
Torre et al., 2006 (79) |
Pioglitazone + sulfonylurea |
77 |
6 months |
Not reported |
Significant decrease in triglyceridelevels in the pioglitazone + sulfonylurea group only Significant improvement inHDL-cholesterol levels |
|
Pioglitazone + metformin |
103 |
|
|
|
Derosa et al., 2004 (85) |
Glimepiride + pioglitazone |
45 |
1 year |
Significant and comparable improvementsin HbA1c at 12 months (p < 0.01) |
Significant improvement across alllipid parameters |
|
Glimepiride + rosiglitazone |
44 |
|
Worsening of multiple lipid parameters |
|
Ginis et al., 2006 (24) |
Pioglitazone + sulfonylurea |
791 |
1 year |
Significant improvement in both groupsfrom baseline Pioglitazone + sulfonylurea: 6.65% Pioglitazone + metformin: 6.61% |
Triglycerides decreased significantlyin both groups (p < 0.0001) Overall reduction of 12.8% for bothgroups combined for total cholesterol Significant improvement in HDL- andLDL-cholesterol levels in both groups |
|
Pioglitazone + metformin |
705 |
|
|
|
PROactive Charbonnel and Scheen,2006 (22); Spanheimeret al., 2006 (78) |
Pioglitazone + sulfonylurea |
508 |
3 years |
Significantly greater improvements overtime in HbA1c vs. placebo (p < 0.001at final visit) |
Significant improvement in triglycerideand HDL-cholesterol levels vs. placebo |
|
Placebo + sulfonylurea |
493 |
|
|
|
Quartet Charbonnel et al., 2005 (21) |
Pioglitazone + sulfonylurea |
319 |
2 years |
HbA1c reduced by 1.03% |
Significant reduction in triglyceridesand greater increase inHDL-cholesterol (p ≤ 0.001) vs.metformin + sulfonylurea |
|
Metformin + sulfonylurea |
320 |
|
HbA1c reduced by 1.16% |
|